论文部分内容阅读
配体制药公司宣布LGD-6972治疗2型糖尿病的Ⅰb期临床试验有较好的安全性、耐受性和药代动力学结果,证实其可剂量依赖性地降低空腹血糖。LGD-6972是胰高血糖素受体拮抗剂,能降低肝生成葡萄糖。试验表明,LGD-6972 5、10和15 mg是安全的且耐受良好。在血液、尿液、心电图和生命体征方面检测均未发现有临床意义的变化,无严重不良反应和停药者。副作用均为1~2级轻中度。随LGD-6972剂量增加,血药浓度呈线性升高,正常人与2型糖尿病患者的药代动力学参数相当,支持每日1次用药。LGD-6972能降低正
Ligand Pharmaceuticals Inc. announced that Phase Ib clinical trials of LGD-6972 in the treatment of type 2 diabetes have shown good safety, tolerability and pharmacokinetic results, confirming its ability to reduce fasting blood glucose in a dose-dependent manner. LGD-6972 is a glucagon receptor antagonist that reduces hepatic glucose production. Experiments have shown that LGD-6972 5, 10 and 15 mg are safe and well-tolerated. In the blood, urine, electrocardiogram and vital signs were detected in the detection of no clinically significant changes, no serious adverse reactions and withdrawal. Side effects are 1 to 2 mild and moderate. As the dose of LGD-6972 increased, the plasma concentration increased linearly. The pharmacokinetic parameters of normal and type 2 diabetic patients were comparable, supporting once-daily administration. LGD-6972 can reduce the positive